Revelation Biosciences Inc REVB says that it observed a significant decrease in viral load with the prophylactic treatment of REVTx-99 in models of COVID-19 infection.
What Happened: REVTx-99 was assessed for prophylactic antiviral activity against delta variant infection in three separate cell lines.
Each cell line expressed sufficient levels of ACEII and TLR4, receptors required to sufficiently demonstrate viral infection as well as REVTx-99 activity, respectively.
Why It Matters: Human primary bronchial/tracheal and alveolar epithelial cells were treated with 250 nanograms per mL (ng/mL) REVTx-99 one hour and 24 hours before infection, respectively.
In both the cell lines, viral load was reduced by more than 50% compared to the non-treated viral assay control.
Human lung epithelial cells were treated with REVTx-99 one hour before infection. Treatment with REVTx-99 at 250ng/mL and 1000ng/mL reduced the number of COVID-19 plaque-forming units by 19% and 29%, respectively, compared to the non-treated viral control.
The Company is identifying a dose range for optimal antiviral efficacy against SARS-CoV-2, additional variants, and other viruses, including rhinovirus, respiratory syncytial virus, and influenza.
Revelation has completed its previously-announced business combination with Petra Acquisition Inc PAIC, a special purpose acquisition company.
Related: Respiratory Viral Infections-Focused Revelation Biosciences Turns To SPAC Deal For NASDAQ Debut.
The Company will start trading on NASDAQ beginning today.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
